Check for updates

OPEN ACCESS

EDITED BY Liqi Shu, Brown University, United States

REVIEWED BY Roopa Biswas, Uniformed Services University of the Health Sciences, United States Amin Safa, Complutense University of Madrid, Spain

*CORRESPONDENCE Mohammad Taheri, I Mohammad.taheri@uni-jena.de Guive Sharifi, I gibnow@yahoo.com

RECEIVED 12 December 2022 ACCEPTED 16 June 2023 PUBLISHED 27 June 2023

CITATION

Ghafouri-Fard S, Shoorei H, Hussen BM, Poornajaf Y, Taheri M and Sharifi G (2023), Interaction between SIRT1 and noncoding RNAs in different disorders. *Front. Genet.* 14:1121982. doi: 10.3389/fgene.2023.1121982

COPYRIGHT

© 2023 Ghafouri-Fard, Shoorei, Hussen, Poornajaf, Taheri and Sharifi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Interaction between SIRT1 and non-coding RNAs in different disorders

Soudeh Ghafouri-Fard¹, Hamed Shoorei^{2,3}, Bashdar Mahmud Hussen⁴, Yadollah Poornajaf⁵, Mohammad Taheri^{6,7}* and Guive Sharifi⁸*

¹Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran, ²Department of Anatomical Sciences, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran, ³Clinical Research Development Unit of Tabriz Valiasr Hospital, Tabriz University of Medical Sciences, Tabriz, Iran, ⁴Department of Clinical Analysis, College of Pharmacy, Hawler Medical University, Erbil, Iraq, ⁵Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran, ⁶Institute of Human Genetics, Jena University Hospital, Jena, Germany, ⁷Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, ⁸Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

SIRT1 is a member of the sirtuin family functioning in the process of removal of acetyl groups from different proteins. This protein has several biological functions and is involved in the pathogenesis of metabolic diseases, malignancy, aging, neurodegenerative disorders and inflammation. Several long non-coding RNAs (lncRNAs), microRNAs (miRNAs) and circular RNAs (circRNAs) have been found to interact with SIRT1. These interactions have been assessed in the contexts of sepsis, cardiomyopathy, heart failure, non-alcoholic fatty liver disease, chronic hepatitis, cardiac fibrosis, myocardial ischemia/reperfusion injury, diabetes, ischemic stroke, immune-related disorders and cancers. Notably, SIRT1-interacting non-coding RNAs have been found to interact with SIRT1 have been identified. These axes are potential targets for design of novel therapies for different disorders. In the current review, we summarize the interactions between three classes of non-coding RNAs and SIRT1.

KEYWORDS

SIRT1, IncRNA, miRNA, circRNA, biomar

Introduction

As a member of the sirtuin family, Sirt1 has a function in removal of acetyl groups from different proteins. This nicotinamide adenosine dinucleotide (NAD)-dependent deacetylase has several biological functions and is involved in the pathogenesis of metabolic diseases, malignancy, aging, neurodegenerative disorders and inflammation (Rahman and Islam, 2011). SIRT1 has a lot of substrates including a number of transcription factors. These transcription factors include p53, FoxO family, HES1, HEY2, PPAR γ , CTIP2, p300, PGC-1 α , and NF- κ B (Haigis and Guarente, 2006; Michan and Sinclair, 2007; Yamamoto et al., 2007; Pillarisetti, 2008). The enzymatic reaction catalyzed by SIRT1 leads to generation of nicotinamide and transfer of the acetyl group of the substrate to cleaved NAD, producing a distinctive metabolite, namely, O-acetyl-ADP ribose (Pillarisetti, 2008).

SIRT1 has an important role in the regulation of energy homeostasis in response to accessibility to nutrients. In the liver tissue, SIRT1 enhances expression of the nuclear

TABLE 1 SIRT1-interacting miRNAs.

Type of diseases	miRNA	Sample	Cell line	SIRT1 expression	Targets and pathways	Discussion	Ref
Sepsis	miR- 181a (Up)	-	RAW264.7	(Down)	Nrf2, p-65, NF- κβ, TNF-α, IL-1β, IL-6, Bcl-2, Bax	Inhibition of miR-181a via targeting SIRT1 by activating Nrf2 and inhibiting NF-κB could attenuate sepsis-induced inflammation and apoptosis	Wu et al. (2021a)
Sepsis	miR- 133a (Up)	Serum samples: sepsis (n = 60), normal group (n = 30), C57BL/6J mice	RAW264.7	(Down)	ALT, AST, IL-1β, IL-6, TNF-α	miR-133a by targeting SIRT1 could aggravate inflammatory responses in sepsis	Chen et al. (2020a)
Sepsis	miR- 195 (Up)	-	NCM460	(Down)	Bcl-2, Bax, elF2α, ATF4, CHOP, GRP78	miR-195 via targeting the SIRT1/eIF2α axis could enhance intestinal epithelial cell apoptosis	Yuan et al. (2020)
Sepsis	miR-197		H9c2	(Down)	Bcl-2, Bax, IL-6, IL-1β, Caspase- 3, p53	miR-197 by modulating SIRT1 could participate cardiomyocyte injury	Liu et al. (2022a)
Septic cardiomyopathy	miR-22 (-)	miR-22-flox mice, aMHC-Cre mice, littermates wild- type (WT) mice	Cardiomyocyte	(Down)	TNF-α, IL-6, IL- 1β, LC3-I/II, p62, Atg7, Caspase-3/ 9, Bax, Bcl-2	Downregulation of miR-22 by targeting SIRT1 could alleviate septic cardiomyopathy	Wang et al. (2021a)
Non-alcoholic steatohepatitis (NAFLD)	miR- 29a (-)	C57BL/6 mice	HepG2	(-)	GSK-3β, CD36, PERK, IRE1α, XBP1s, CHOP	miR-29a via modulating the GSK-3β/SIRT1 could ameliorate mouse non- alcoholic steatohepatitis	Yang et al. (2020)
NAFLD	miR- 34a (Up)	Wistar rats	-	(Down)	FXR, p53, ALT, AST, γ-GGT, TNF-α, IL-6,	Alteration of miR-34a/ SIRT1/FXR/p53 axis could induce NAFLD in rats	Alshehri et al. (2021)
Chronic hepatitis C (CHC)	miR- 34a (Up)	CHC (n = 41), healthy control samples (n = 18)	-	(Down)	p53, TBA, AST, ALT	miR-34a via mediating the SIRT1/p53 axis could enhance liver fibrosis in patients with chronic hepatitis	Li et al. (2020a)
Hepatic I/R Injury	miR- 182 (-)	Black/Swiss mice, C57BL/6J WT mice	Hepatocyte	(Down)	XBP1, NLRP3, ALT, IL-1β, TNF- α, IL-18, Caspase-1	SIRT1 via modulating the miR-182-mediated XBP1/ NLRP3 axis could alleviate hepatic IR injury	Li et al. (2021a)
Cardiac Fibrosis	miR- 128 (Up)	C57BL/6 J mice	H9c2	(Down)	PIK3R1, p53, p62, Bcl-2, Bax,	Downregulation of miR- 128 via targeting the SIRT1/ PIK3R1 axis could	Zhan et al. (2021)
					Beclin-1, LC3-I/ II, AKT, mTOR	ameliorate cardiac dysfunction	
Congestive heart failure (CHF)	miR-22 (-)	C57BL/6 mice	Cardiomyocyte	(Down)	PGC-1a, TFAM, p62, LC3-I/II	Downregulation of miR-22 by targeting SIRT1/PGC-1α could alleviate CHF.	Wang et al. (2021b)
HF	miR- 199a (Up)	C57Bl/6J mice	CMs, CFs, CECs	(Down)	P300, Yy1, sST2	miR199/SIRT1/P300 axis via upregulating the circulation of soluble sST2 isoform could modulate heart failure	Asensio-Lopez et al. (2021)
Myocardial I/R Injury	miR- 29a (Up)	C57BL/J6	Н9с2	(Down)	NLRP3, IL-1/6, IL-1β, TNF-α, eNOS, iNOS, Caspase-1	Downregulation of miR- 29a by targeting SIRT1 and inhibiting NLRP3- mediated pyroptosis could ameliorate myocardial I/R Injury	Ding et al. (2020)

TABLE 1 (Continued) SIRT1-interacting miRNAs.

Type of diseases	miRNA	Sample	Cell line	SIRT1 expression	Targets and pathways	Discussion	Ref
Cardiotoxicity	miR-200a- 3p (Up)	Wistar rats	H9c2, 293T	(-)	PEG3, NF-κβ, Bax, Bcl-2, IKK, p65, ΙκΒα	miR-200a-3p via modulating SIRT1/NF-ĸB axis and by targeting PEG3 could aggravate cardiotoxicity	Fu et al. (2021)
Acute myocardial	miR-181a-	-	H9C2	(-)	Bcl-2, Bax,	miR-181a-5p via regulating	Qi et al. (2020)
infarction (AMI)	5p (-)				Caspase-3	SIRT1 could involve cardiomyocyte apoptosis induced by hypoxia-reoxygenation	
AMI	miR-124- 3p (Up)	SD rats	H9C2	(Down)	FGF21, CREB, PGC1-α, g IL-1α, IL-1β, IL-2/6, IFN-γ, TNF-α, Bax, Bcl-2, Caspase-3	miR-124-3p via targeting SIRT1 by modulation FGF21/CREB/PGC1a axis could regulate cell apoptosis and oxidative stress of acute myocardial infarction	Wei et al. (2021)
Osteoarthritis (OA)	miR-30b- 5p (Up)	OA tissue samples ($n = 40$) and adjacent ($n = 15$) normal tissue samples, SD rats	HC-A,	(Down)	FoxO3a, NLRP3, NF-κβ, IL-1β, IL- 6/18, TNF-α, Bax, Caspase-1/3, MMP-3/13, ASC	NF-kB-inducible miR-30b- 5p via modulating SIRT1- FoxO3a-mediated NLRP3 inflammasome could aggravate joint pain	Xu et al. (2021a)
OA	miR- 122 (Up)	OA tissue samples (n = 29), normal cartilage tissue samples (n = 29)	-	(Down)	Collagen-II, Aggrecan, MMP- 13, ADAMTS4	miR-122 via targeting SIRT1 could regulate chondrocyte extracellular matrix degradation in osteoarthritis	Bai et al. (2020)
Kidney Injury	miR- 34a (Up)	Kunming mice	-	(Down)	p53, TNF-α, IL-6, IL-1β, Caspase-9, Bax, Bcl-2	miR-34a/SIRT1/p53 axis could modulate kidney injury	Hao et al. (2021)
Acute kidney injury (AKI)	miR-183- 3p (Up)	SD rats	NRK-52E	(Down)	PUMA, FOXO3a, TGF-β1, <i>a-</i> SMA, Vimentin,E- Cadherin	Depletion of miR-183-3p via the SIRT1/PUMA/ FOXO3a axis could improve renal tubulointerstitial fibrosis after AKI.	Li et al. (2021b)
Diabetic nephropathy (DN)	miR-150- 5p (Up)	(n = 60) diabetes mellitus patients, C57BL/6J mice	Podocyte	(Down)	p53, p62, AMPK, p-cadherin, ZO-1, LC3-I/II	Downregulation of miR- 150-5p by targeting the SIRT1/p53/AMPK axis could ameliorate diabetic nephropathy	Dong et al. (2021)
DN	miR- 34a (Up)	C57BL/6J mice	Podocyte	(Down)	p53, LC3A/B-I, LC3A/B-II	The p53/miR-34a/ SIRT1 axis inhibition could ameliorate podocyte injury in DN.	Liang et al. (2021)
Cerebral I/R Injury	miR-19a/ b-3p (Up)	SD rats	-	(Down)	FoxO3, SPHK1, NF-κβ p65, TNF- α, IL-6, IL-1β	miR-19a/b-3p via targeting the SIRT1/FoxO3/ SPHK1 axis could promote inflammation during cerebral I/R injury	Zhou et al. (2021)
SCI	miR-324- 5p (Up)	SD rats	PC12	(Down)	Bcl-2, Caspase-3, Bax, TNF-α, IL-1β	Silencing miR-324-5p by modulating SIRT1 could alleviate rats SCI.	Wang et al. (2021c)
CCIS	miR-34c- 5p (Up)	SD rats	-	(Down)	TNF-α, IL-6, IL- 1β, STAT3	Downregulation of miR- 34c-5p via targeting the SIRT1/STAT3 axis could alleviate neuropathic pain	Mo et al. (2020)
Epilepsy	miR-135a- 5p (Up)	-	BV2	(-)	Caspase-3/9	Downregulation of miR- 135a-5p via targeting SIRT1 could protect glial cells against apoptosis in epilepsy	Wang et al. (2021d)

TABLE 1 (Continued) SIRT1-interacting miRNAs.

Type of diseases	miRNA	Sample	Cell line	SIRT1 expression	Targets and pathways	Discussion	Ref
MDD	miR- 138 (Up)	C57BL/6J mice	-	(Down)	PGC-1α, FNDC5, BDNF	miR-138 by targeting SIRT1 could enhance depressive-like behaviors in the hippocampus	Li et al. (2020b)
Migraine	miR-34a- 5p (-)	SD rats	trigeminal ganglionic cells	(-)	COX2, PGE2, p65, NF-κβ, IL- 1β, IL-13	miR-34a-5p via inhibiting SIRT1 could enhance the IL-1 β /COX2/PGE2 axis and stimulate the release of CGRP in trigeminal ganglion neurons in rats	Zhang et al. (2021a)
DFUs	miR-489- 3p (-)	SD rats	HUVECs	(-)	VEGF, Bcl-2, Bax, Caspases-3/9, PI3K, AKT, eNOS, iNOS	Alteration in miR-489-3p/ SIRT1 axis could enhance wound healing in DFU.	Huang et al. (2021a)
DR	miR- 221 (Up)	-	hRMEC	(Down)	Nrf2, Caspase-3 Bax, Bcl-2, Keap-1	Overexpression of miR-221 via inhibiting SIRT1 could enhance apoptosis of hRMEC.	Chen et al. (2020b)
ALI	miR-146a- 3p (Up)	SD rats	BEAS-2B	(Down)	NF-κβ, TNF-α, IL-1β, IL-4, IL-6, IL-10	Depletion of miR-146a-3p via upregulating SIRT1 and mediating NF-κB could attenuate ALI.	Yang and Li (2021)
UUO	miR-155- 5p (Up)	-	NRK-49F	(Down)	α-SMA, Collage-I, Fibronectin	miR-155-5p via modulating SIRT1 promotes renal interstitial fibrosis	Wang et al. (2021e)
-	miR- 217 (Up)	-	HUVECs	(-)	p53, SA-β-gal	miR-217 via modulating the SIRT1/p53 axis could enhance endothelial cell senescence	Wang et al. (2021f)
-	miR-204- 5p (-)	C57BL/6J	HC11	(-)	PPARy	miR-204-5p by targeting SIRT1 could enhance lipid synthesis in mammary epithelial cells	Zhang et al. (2020a)
-	miR-128- 3p (Up)	-	BMSCs	(-)	IL-6, IL-1β, MMP-9, MCP-1	MiR-128-3p by regulating SIRT1 expression could mediate inflammatory responses in BMSCs	Wu et al. (2020)
-	miR-34a- 5p, miR- 34a-3p (-)	Human submandibular gland tissue samples (n = 114), human parotid gland tissue samples (n = 114), serum samples (n = 114), SD rats	SMG-C6,	(-)	CTRP6, AMPK, TNF-α, Bcl-2, Bax Caspase-3/8/9/12, Cytochrome-C,	CTRP6 via targeting the AMPK/SIRT1 axis by modulating miR-34a-5p expression could attenuate TNF-α-induced apoptosis	Qu et al. (2021)
-	miR-146a- 5p (Up)	(n = 45) bone tissue samples, KO mice	MC3T3-E1	(-)	Collagen-I	miR-146a-5p via targeting SIRT1 could regulate bone mass	Zheng et al. (2021)
PCa	miR-	-	AsPC-1,	(-)	PGC-1a, NRF2,	miR-373 via modulating	Yin et al. (2021)
	373 (-)		PANC-1		Bax, Bcl-2, Caspase-3/8/9, PARP, eNOS, iNOS	the SIRT1/PGC-1α/ NRF2 axis could suppress cell proliferation in pancreatic cancer cells	
CRC	miR-	CRC tissue and	НСТ-8,	(-)	NF-κβ, p65, B7-	miR-34a via modulating	Meng et al.
	34a (Up)	ANT samples, DAB1/J mice, NOD-SCID mice	HCT-116,	-	H3, TNF-a	the SIRT1/NF-κB and B7- H3/TNF-α axis could induce	(2021)
			CHO, PBMCs			immunosuppression in colorectal cancer	

TABLE 1 (Continued) SIRT1-interacting miRNAs.

Type of diseases	miRNA	Sample	Cell line	SIRT1 expression	Targets and pathways	Discussion	Ref
cSCC	miR-199a- 5p (Down)	BALB/c nude mice	A431, NHSF	(Up)	CD44ICD, OCT4, SOX2, Nanog	miR-199a-5p by targeting SIRT1 and CD44ICD cleavage signaling could repress stemness of cSCC stem cells	Lu et al. (2020)




FIGURE 1

SIRT1 works with a lot of molecules, some of which are transcription factors. p53, the FoxO family, HES1, HEY2, PPAR, CTIP2, p300, PGC-1, and NF-B are all transcription factors. Dysregulation of SIRT1-targeting miRNAs plays a role in the pathogenesis of sepsis and its complications, chronic hepatitis, ischemia/reperfusion (I/R) injury to the liver and heart, cardiac fibrosis, myocardial infarction, osteoarthritis, diabetic nephropathy, and a number of malignant diseases like colorectal cancer.

receptor PPARa, thus regulating lipid homeostasis. Deletion of Sirt1 in this tissue has been shown to impair PPARa signaling and decrease β -oxidation of fatty acids, resulting in the development of hepatic steatosis, induction of inflammatory responses in liver, and endoplasmic reticulum stress (Purushotham et al., 2009).

In addition to the regulation of metabolic pathways, SIRT1 is involved in the carcinogenic processes. Its expression has been found to be increased in both hematological malignancies (Bradbury et al., 2005) and solid tumors (Huffman et al., 2007; Stünkel et al., 2007). Possibly acting as an oncogene, SIRT1 interacts with p53 and induces its deacetylation at its C-terminal Lys382 residue (Vaziri et al., 2001), thus inactivating this tumor suppressor.

In fact, SIRT1 is involved in a variety of human disorders including malignant and nonmalignant conditions. Recently, researchers

have focused on identification of the interaction between noncoding RNAs and SIRT1 in these disorders. These investigations have led to identification of a number of long non-coding RNAs (lncRNAs), microRNAs (miRNAs) and circular RNAs (circRNAs) that regulate expression of SIRT1. In the current review, we provide an overview of these non-coding RNAs.

SIRT1-interacting miRNAs

A class of non-coding RNAs known as miRNAs regulate gene expression by binding to specific target genes in distinct pathways, thereby modulating the expression of various genes (Ghafouri-Fard et al., 2021a; Hussen et al., 2021; Hussen et al., 2022a). Mature

TABLE 2 SIRT1-interacting circRNAs.

Type of diseases	Circular-RNAs	Sample	Cell line	SIRT1 expression	Targets and pathways	Discussion	Ref	
T2DM	hsa_circ_0115355 (Down)	Serum samples of T2DM patients (n = 20)	INS-1	(Down)	miR-145	hsa_circ_0115355 via targeting the miR-145/SIRT1 axis could enhance pancreatic β -cell function	Dai et al. (2022)	
DN	HIPK3 (Down)	HIPK3 (Down) -	НК-2	(Down)	miR-326,	Circ-HIPK3 via modulating the	Zhuang et al.	
				_	miR-487a-3p,	miR-326/miR-487a-3p/ SIRT1 axis could alleviate high	et al. (2021)	
					Caspase-3,	glucose toxicity to HK-2 Cells		
					Bax, Bcl-2	_		
RA	hsa_circ_0044235 (Down)	Serum samples of RA $(n = 48)$,	FLSs	(Down)	miR-135b-5p, Caspase-1,	hsa_circ_0044235 could regulate pyroptosis via	Chen et al.	
		healthy control group $(n = 36)$,			TNF-α, IL-6,	modulating miR-135b-5p- SIRT1 axis	(2021)	
		DBA/1 J mice			IL-1β, NLRP3	-		
CCI	circ_0000296 (Down)	C57BL/6J mice	HT22	(Down)	miR-194-5p, Runx3	Upregulation of circ_0000296 via miR-194-5p/ Runx3 axis could increase transcription of SIRT1 and inhibit apoptosis of hippocampal neurons	Huang et al. (2021b)	
OA	Circ_0001103 (Down)	OA samples (n = 30), normal tissues (n = 10), OA serum (n = 10) and normal (n = 10) samples	Chondrocyte	(Down)	miR-375, IL-1β, COL2A1, ADAMTS4	Circ_0001103 via targeting miR-375 by upregulating SIRT1 could alleviate IL-1β- induced chondrocyte cell injuries	Zhang et al. (2021b)	
IDD	CIDN (Down)	IDD tissue	NP	(Down)	miR-34a-5p,	Circ-CIDN via the miR-34a-	Xiang	
		samples (n = 30) and healthy control tissues			MMP-3/13, Bax, caspase-3, Bcl-2,	 5p/SIRT1 axis could mitigate compression loading-induced damage 	et al. (2020)	
		(n = 50), SD rats			Collagen-II	-		
GC	NOP10 (Up)	10 pairs of GC and	GES-1, AGS,	(Up)	miR-204, NF-κβ,	Circ-NOP10 by regulating the	Xu et al.	
		ANT samples	MNK-45,		E-cadherin, p65, Vimentin, Bcl-2,	miR-204/SIRT1 axis could mediate gastric cancer	(2021b)	
			HGC-27,	-	Caspase-3, Bax	progression		
			BGC-823					
Glioma	Circ-0082374 (Up)		A172, BT325,	(-)	miR-326,	Knockdown of Circ-0082374	Wang	
		(n = 42), non- cancer tissue samples $(n = 28)$,			ММР-9,	by modulating the miR-326/ SIRT1 axis could inhibit viability, migration, invasion,	et al. (2020)	
		BALB/c nude mice	SHG44, HA1800		E-cadherin, Vimentin	and glycolysis of glioma cells		

miRNAs are formed by further processing of pre-miRNAs, which are formed from the transcribed nucleic acids that make up primary miRNAs. Several miRNAs have been shown to target SIRT1, thus regulating its expression. Dysregulation of SIRT1-targeting miRNAs is involved in the pathogenesis of sepsis and its complications, nonalcoholic fatty liver disease (NAFLD), chronic hepatitis, hepatic and myocardial ischemia/reperfusion (I/R) injury, cardiac fibrosis, heart failure, myocardial infarction, osteoarthritis, kidney injury, diabetic nephropathy, cerebral I/R Injury, spinal cord injury, epilepsy and a number of malignant conditions (Table 1; Figure 1). In sepsis, upregulation of miR-181a (Wu Z. et al., 2021), miR-133a (Chen L. et al., 2020) and miR-195 (Yuan et al., 2020) has been shown to lead to downregulation of SIRT1 and aggravation of inflammatory responses. miR-29a, miR-34a and miR-182 are among SIRT1-interacting miRNAs being involved in the pathogenesis of hepatic disorders. For instance, miR-29a via modulating the GSK-3 β /SIRT1 could ameliorate mouse non-alcoholic steatohepatitis (Yang et al., 2020). Alterations in the miR-34a/SIRT1/FXR/ p53 axis have been found to induce NAFLD in rats (Alshehri et al., 2021). Moreover, miR-34a via mediating the SIRT1/

p53 axis could enhance liver fibrosis in patients with chronic hepatitis (Li X. et al., 2020).

miR-128 has been shown to be involved in the pathogenesis of chronic angiotensin II infusion-induced cardiac remodeling through modulation of SIRT1. Silencing this miRNA in the heart tissues of mice could ameliorate angiotensin II-induced cardiac dysfunction, hypertrophy, fibrosis and oxidative stress damage. Angiotensin II could induce upregulation of miR-128 in cell culture. Treatment of cells with miR-128 antagomir could attenuate angiotensin II -induced apoptosis and oxidative damage possibly through targeting the SIRT1/p53 pathway. Suppression of this miRNA could also activate PIK3R1/Akt/ mTOR pathway, restrain angiotensin II-induced autophagy in cardiomyocytes, and mitigate oxidative stress and apoptosis (Zhan et al., 2021).

SIRT1-interacting miRNAs are also involved in the pathogenic processes in the acute myocardial infarction. Suppression of miR-29a has been shown to protect against myocardial I/R injury through influencing expression of SIRT1 and subduing oxidative stress and NLRP3-associated pyroptosis (Ding et al., 2020). In addition, miR-200a-3p has been found to aggravate doxorubicin-induced cardiotoxic effects through targeting PEG3 via SIRT1/NF- κ B signaling

pathway (Fu et al., 2021). miR-181a-5p is another miRNA which participates in the cardiomyocyte apoptosis induced by hypoxia-reoxygenation via regulation of SIRT1 (Qi et al., 2020). Moreover, an experiment in an animal model of acute myocardial infarction has shown that miR-124-3p targets SIRT1 to influence cell apoptosis, inflammatory responses, and oxidative stress through regulation of the FGF21/CREB/PGC1 α axis (Wei et al., 2021). Besides, miRNAs that modulate expression of SIRT1 can affect pathogenesis of heart failure. For instance, downregulation of miR-22 by targeting SIRT1/PGC-1 α could alleviate this disorder (Wang et al., 2021b). Finally, miR199/SIRT1/P300 axis has apotential function in the patheticlogy of this disorder (Asensio-Lopez et al., 2021).

Lastly, three SIRT1-interacting miRNAs have been revealed to participate in the carcinogenesis. miR-373 is a tumor suppressor miRNA that inhibits proliferation of pancreatic cancer cells through influencing activity of SIRT1/PGC-1 α /NRF2 axis (Yin et al., 2021). On the other hand, miR-34a acts as an immunosuppressive miRNA in colorectal cancer via regulation of SIRT1/NF- κ B/B7-H3/TNF- α axis (Meng et al., 2021). Lastly, miR-199a-5p has a role in repression of stemness of squamous cell carcinoma cells through influencing activity of SIRT1 and CD44ICD cleavage signaling (Lu et al., 2020).




FIGURE 2

CircRNAs have been proven to serve as molecular sponges for miRNAs, thereby influencing the expression of miRNA targets. SIRT1 has been found to be the target of miRNA genes, which were already being sponged by different types of circRNAs that prevented or enhanced gene expression.

TABLE 3 SIRT1-interacting IncRNAs.

Type of diseases	LncRNA	Sample	Cell line	SIRT1 expression	Target and pathways	Discussion	Ref
RA	GAS5 (Down)	Serum samples of RA patients $(n = 35)$ and Serum samples of healthy control (n = 35)	RA-FLSs	(Down)	miR-222-3p, TNF- α,IL-1β, IL-6, Bcl-2, Bax, Caspase-3/9	GAS5 via regulating the miR-222-3p/Sirt1 axis could alleviate RA.	Yang et al. (2021)
Atherosclerosis	LincRNA-p21 (Down)	Serum samples of AS patients (n = 25), C57BL/6 mice	HAECs, 293T	(Down)	miR-221, Pcsk9, Caspase-3, Bcl-2, Bax	LncRNA-p21 via modulating the miR-221/ SIRT1/Pcsk9 axis could alleviate atherosclerosis progression	Wang et al. (2021g)
SARI	GAS5 (Down)	C57BL/6 mice	НК-2	(Down)	miR-579-3p, Nrf2, IL- 1β, IL-18, NLRP3, PGC-1α, Caspase-1,	GAS5 via inhibiting the miR-579-3p by activating the SIRT1/PGC-1a/ Nrf2 axis could reduce cell pyroptosis in SARI.	Ling et a (2021)
OA	MCM3AP-AS1	30 pairs of OA and	CHON-001,	(Down)	miR-138-5p,	MCM3AP-AS1 via	Shi et al.
	(Down)	ANTs	ATDC5		IL-6, IL-8,	modulating the miR-138- 5p/SIRT1 axis could	(2021)
					TNF-α	protect chondrocytes from IL-1β-induced inflammation	
Sepsis	TUG1 (Down)	C57BL/6 mice	RAW264.7	(Down)	miR-9-5p, TNF-α, MCP-1, IL-6, IL-10, iNOS, Arg-1,	TUG1 via impairing miR- 9-5p targeted SIRT1 inhibition could confer anti-inflammatory macrophage polarization in sepsis effects	Ma et al. (2021)
DN	TUG1 (Down)	-	НК-2	SIRT1 (Down)	miR-29c-3p, ERS, Bax, Bcl-2, caspase-3/12, GRP78, CHOP, PERK, eIF-2α	The TUG1/miR-29c-3p/ SIRT1 axis could regulate endoplasmic reticulum stress-mediated cell injury in DN.	Wang et al. (2021h)
Ischemic Stroke	SNHG8 (-)	C57BL/6 mice	BMEC	(Down)	miR-425-5p, NF-κβ, caspase-3, ZO-1, Occludin, TNF-α, IL- 1β, IL-6	SNHG8 via regulating miR-425-5p mediated SIRT1/NF-κβ axis could attenuate blood-brain barrier damage	Tian et a (2021)
Ischemic Stroke	SNHG7 (Down)	C57BL/6 mice	PC12,	(Down)	miR-9	SNHG7 by targeting the miR-9/SIRT1 axis could alleviate damage in PC12 Cells	Zhou et al. (2020)
Cerebral I/R Injury	SNHG15 (Up)	-	SH-SY5Y	(-)	miR-141, TNF-α, IL- 1β, IL-6, iNOS, p65	SNHG15 by targeting the miR-141/SIRT1 axis could enhance oxidative stress damage	Kang et al. (2021)
Myocardial I/R	Oip5-as1 (Down)	SD rats	NRVMs,	(Down)	miR-29a, AMPK, PGC1α, LDH, ROS,	Oip5-as1 via activating the SIRT1/AMPK/PGC1α axis	Niu et al (2020)
Injury	(Down)		H9c2		Bax, Bcl-2, Cyt-c, caspase-3, 15-F2t- isoprostane, SOD, GPx	by sponging miR-29a could attenuate myocardial I/R injury	(2020)
MI	ILF3-AS1 (Down)	-	H9c2, 293T	(-)	miR-212-3p, PI3K, AKT, Bcl-2, Bax, caspase-3/9	ILF3-AS1 via targeting the miR-212-3p/SIRT1 axis and the PI3K/Akt pathway could regulate MI.	Zhang et al. (2020c)
АМІ	ANRIL (Up)	-	H9c2	(-)	miR-7-5p, Bcl-2, Bax, Caspase-3/9, HIF-1α	ANRIL via targeting the miR-7-5p/SIRT1 axis could protect H9c2 cells against hypoxia-induced injury	Shu et al (2020)


Type of diseases	LncRNA	Sample	Cell line	SIRT1 expression	Target and pathways	Discussion	Ref
Diabetes	TUG1 (Down)	C57BL/6J mice	3T3-L1	(Down)	miR-204, AMPK, ACC, ATGL, PGC-1a, PPARa, UCP-1	TUG1 via targeting SIRT1 by regulating miR- 204 could enhance brown remodeling of white adipose tissue in diabetic mice	Zhang et al. (2020d)
NSCLC	SNHG10 (Down)	60 pairs of NSCLC and ANT samples	H1581, H1703	(-)	miR-543	SNHG10 via sponging miR-543 could upregulate tumor suppressive SIRT1 in NSCLC.	Zhang et al. (2020b)
HCC	SNHG7 (Up)	25 pairs of HCC and	THLE-3,	(Up)	miR-34a, NLRP3,	SNHG7 via targeting the miR-34a/SIRT1 axis could inhibit NLRP3-dependent	Chen et al. (2020c)
		ANT samples	293T, HepG2,		Caspase-1, IL-1β		
			SK-hep-1			pyroptosis	
CRC	GAS5 (Down)	AS5 (Down) 75 pairs of CRC and ANT samples, Wistar rats	HT29,	(Up)	LC3 I/II. Beclin-1, Bcl- miR-34a/mTOR/	SIRT1 axis could inhibit	Zhang et al. (2021c)
			HCT116,	_			
			SW480,				
			SW620				
AML	UCA1 (Up)	Serum samples:	KG-1a, THP-1,	(-)	miR-204, Caspase-3,	Silencing UCA1 via	Liang
		AML (n = 27), normal (n = 9)	HS-5	_	iNOS, COX-2	targeting miR-204 by repressing SIRT1 could accelerate apoptosis in pediatric AML.	et al. (2020)
RB	KCNQ1OT1	3 pairs of RB and	hTERT RPE-1,	(Down)	miR-124,	KCNQ1OT1 by targeting the miR-124/SP1 axis could modulate RB cell	Zhang
	(UP)	P) ANTs, nude mice	Y79, WERI- Rb-1		SP1, Cyclin-D1,		et al. (2021d)
					Caspase-3, Vimentin,	proliferation and invasion	
					E/N-cadherin,		

SIRT1-interacting circRNAs

Circular RNAs (CircRNAs) are common in all animals, from viruses to mammals. They are single-stranded, endogenous covalently closed RNA molecules with highly stability. The biosynthesis, regulation, localization, destruction, and modification of circRNAs have all seen great progress (Sayad et al., 2022). CircRNAs play a role in a wide range of human disorders, particularly malignancies (Ghafouri-Fard et al., 2021b; Ghafouri-Fard et al., 2022). The impact of SIRT1interacting circRNAs in the regulation of SIRT1 has been assessed in diabetes and its complications, rheumatoid chronic cerebral ischemia, arthritis, osteoarthritis, intervertebral disc degeneration as well as malignant disorders, particularly glioma (Table 2). All of these circRNAs have been shown to act as molecular sponges for miRNAs to subsequently affect expression of miRNAs targets (Figure 2). For instance, hsa_circ_0115355 has been found to regulate activity of miR-145/SIRT1 axis, thus enhancing function of pancreatic β cells in patients with type 2 diabetes mellitus (Dai et al., 2022). CircHIPK3 is another circRNA which participates in the pathogenesis of diabetic complications. Expression of this circRNA has been significantly reduced in HK-2 cells following exposure with high glucose. Forced upregulation of circHIPK3 could reverse high glucose-induced pathologic events in HK-2 cells. SIRT1 has been found to be the target of miR-326 and miR-487a-3p, two downstream genes of circHIPK3. Silencing of these two miRNAs could induce proliferation and decrease apoptosis in high glucose-induced HK-2 cells. Taken together, upregulation of circHIPK3 can reduce the effects of high glucose in HK-2 cells via sponging miR-326 or miR-487a-3p and influencing expression of SIRT1 (Zhuang et al., 2021).

Hsa_circ_0044235 is another circRNA which has been shown to be downregulated in patients with rheumatoid arthritis (RA). Downregulation of this circRNA has been correlated with low levels of SIRT1 expression in these patients. Overexpression of hsa_circ_0044235 could attenuate joint inflammation, cell apoptosis, and joint injury, and reduce NLRP3-mediated pyroptosis but increasing SIRT1 expression. Upregulation of this circRNA could also inhibit caspase-1 content. Mechanistically, hsa_circ_0044235 increases expression of SIRT1 through sponging miR-135b-5p (Chen et al., 2021).

CircularNOP10 and circ0082374 are two putative oncogenic circRNAs that regulate expression of SIRT1. CircularNOP10 has a role in induction of progression of gastric cancer through



regulation of miR-204/SIRT1 pathway (Xu J. et al., 2021). In glioma cells, circ0082374 has a role in induction of cell viability, migration, invasion and glycolysis through regulation of miR-326/SIRT1 axis (Wang et al., 2020).

SIRT1-interacting lncRNAs

Transcripts larger than 200 nt are known as long non-coding RNAs (lnRNAs), which cannot code for proteins and may possess small open reading frames (ORFs). Because they interact with various proteins, mRNAs and DNA sequences, lncRNAs play significant roles in a number of disorders (Sabaie et al., 2021; Hussen et al., 2022b). GAS5, LincRNA-p21, MCM3AP-AS1, TUG1, SNHG7, SNHG8, SNHG10, SNHG15, Oip5-as1, ILF3-AS1, ANRIL, UCA1 and KCNQ1OT1 are examples of lncRNAs that regulate expression of SIRT1 through sponging miRNAs. These lncRNAs can affect pathogenesis of RA, atherosclerosis, sepsis-associated renal injury (SARI), diabetic nephropathy, ischemic stroke and a number of malignant conditions (Table 3). For instance, GAS5 via regulating the miR-222-3p/Sirt1 axis could alleviate RA (Yang et al., 2021). Moreover, GAS5 via inhibiting the miR-579-3p and activating the SIRT1/PGC-1α/Nrf2 axis could reduce cell pyroptosis in SARI (Ling

et al., 2021). In the context of osteoarthritis, MCM3AP-AS1 via modulating the miR-138-5p/SIRT1 axis could protect chondrocytes from IL-1 β -induced inflammation (Shi et al., 2021).

SIRT1-interacting lncRNAs have also been shown to affect pathogenesis of malignant conditions. For instance, SNHG10 has been found to sponge miR-543 in non small cell lung cancer (Zhang Z. et al., 2020). Moreover, SNHG7 has been demonstrated to inhibit NLRP3-associated pyroptosis through regulating miR-34a/SIRT1 axis in liver cancer (Chen Z. et al., 2020). GAS5 can inhibit malignant progression of colorecatl cancer cells through regulating macroautophagy and forming a negative feedback loop with the miR-34a/mTOR/SIRT1 axis (Zhang HG. et al., 2021). On the other hand, UCA1 has a role in induction of cell proliferation and suppression of apoptosis through affecting expression of SIRT1 and miR-204 in pediatric AML (Liang et al., 2020). The known interactions that SIRT1 has with a variety of lnRNAs are illustrated in Figure 3.

A number of therapeutic agents such as anthocyanins, ginsenoside-R3, dexmedetomidine hydrochloride, berberine, sorafenib, 17 β -Estradiol, phenylpyridinium, tetrahydroxy stilbene glycoside, cisplatin, resveratrol, sulforaphane and liraglutide have been found to affect expression of non-coding RNAs/SIRT1 axes (Table 4). For instance, experiments in animal model of asthma

TABLE 4 Effects of drugs on SIRT1-interacting ncRNAs.

Type of diseases	Drug	Non- coding RNAs	Sample	Cell line	SIRT1 expression	Target	Discussion	Ref
Asthma	Anthocyanins (Anth)	miR-138- 5p (Up)	Balb/c mice; treated with 250 mg/kg Anth before each	HBE; treated with 10 μg/mL Anth for 1 h	(-)	NF- κβ p65,	Anth via targeting the miR-138-5p/SIRT1 axis by downregulating NF-κβ	Liu et al. (2022b)
			atomization for 1 h	Anui ioi i ii		IL-4/ 5/13,	could inhibit airway inflammation in asthmatic mice	
						IFN-γ	astimatic mice	
Sepsis	Ginsenoside- R3 (Rg3)	TUG1 (-), miR- 200c-3p	C57BL/6 mice; treated with 20 mg/kg Rg3, I.P,	Hepatocyte; pretreated with 25 µM	(Down)	LC3-I/II, p62, Beclin-1,	Rg3 by modulating the TUG1/miR-200c-3p/ SIRT1 axis could alleviate	Wu et al. (2021b)
			for 1 h	Rg3 for 6 h		PGC1-a,	septic liver injury	
						АМРК	-	
LI	Dexmedetomidine hydrochloride (DEX)	TUG1 (-), miR-194	-	WRL-68; pretreated with 0.01, 0.1, and 1, 5 nM DEX	(Down)	Bax, Bcl-2, TNF-α,	DEX by activating the TUG1/miR-194/ SIRT1 axis could inhibit hepatocyte inflammation	Gu et al. (2021)
				for 1 h		IL-1β, IL-6	and apoptosis	
Insulin resistance	Berberine (BBR)	miR- 146b (-)	C57BL/6J mice; treated with 5, 10 mg/kg/day, I.P, for 4 weeks,	HepG2; treated with 5–30 µM BBR for 24h and 48 h	(Down)	FOXO1	BBR by regulating the miR-146b/SIRT1 axis could ameliorate hepatic insulin resistance	Sui et al. (2021)
Liver cancer	Sorafenib	miR-	TCGA and GEO	HepG2, PLC,	(-)	LC3-I/II,	miR-425 via SIRT1 to promote sorafenib resistance could regulate lipophagy in liver cancer	Sun
		425 (-)	databases	Hep3B, Huh7, MIHA; treated with 10 μM for 48 h		ATGL		et al. (2021)
РМОР	17β-Estradiol (E2)	H19 (Down), miR- 532-3p	Bone tissue (n = 10), serum samples (n = 10), control group (n = 10), Wistar rats; treated with 0.5 mg/kg/day E2 subcutaneously	BMSCs; treated with 10 ⁻⁷ M E2 for 14 days	(Down)	ALP, RUNX2,	E2 via targeting the miR- 532-3p/SIRT1 axis could enhance the expression of H19 to regulate osteogenic differentiation	Li et al. (2021c)
PD	Phenylpyridinium	miR-	FVB littermate wild-	SH-SY5Y;	(Down)	p53,	Upregulation of miR-132	Qazi
	(MPP)	132 (-)	type mice	treated with 1.25 and 2.5 mM MPP, for 12, 24, 48 h		NF-ĸB	via activating the SIRT1/ p53 axis could induce PD.	et al. (2021)
-	Tetrahydroxy Stilbene Glycoside (TSG)	miR- 34a (Up)	-	HUVECs; pretreated with 20, 40 µg/ml TSG for 24 h	(Down)	PAI- 1, p21	TSG via targeting the miR-34a/SIRT1 axis could attenuate endothelial cell premature senescence	Zhang et al. (2022)
AKI	Cisplatin (DDP)	miR-132- 3p (-)	C57BL/6J mice; treated with 20 mg/kg DDP for 24, 48 h	HK-2; treated with 5 μg/ml DDP for 24, 48 h	(Down)	NF-κβ,	miR-132-3p via targeting NF-κβ by modulating SIRT1 could promote DDP-induced apoptosis in renal tubular epithelial cells	Han et al. (2021)
BLC	DDP	MST1P2 (-), miR- 133b	-	SW 780/DDP, RT4/DDP	(-)	p53, Caspase- 3	LncRNA MST1P2/miR- 133b axis via the SIRT1/ p53 axis can influence chemoresistance to DDP- based therapy	Chen et al. (2020d)

Type of diseases	Drug	Non- coding RNAs	Sample	Cell line	SIRT1 expression	Target	Discussion	Ref
-	Resveratrol (RSV)	miR- 155 (-)	-	N9; treated with 10 μM RSV for 1 h	(-)	AMPK, NLRP3, NF-κβ,	RSV via targeting the SIRT1/AMPK axis could inhibit	Tufekci et al. (2021)
						IL-1β, IL-18	NLRP3 inflammasome- induced pyroptosis and miR-155 expression in microglia	
-	Sulforaphane (SFN)	miR-		HUVECs;	(-)	Nrf2,		Li et al.
		34a (Up)		pretreated with 1.0 μmol/l SFN for 4, 8, 12 h		ARE		(2021d)
DN	Liraglutide (LRG) miR- 34a (-) SD rats; treated with - 6 mg LRG subcutaneously for	-	(-)	AST, ALT, HIF-1α,	LRG via targeting the miR-34a/SIRT1 axis could regulate kidney and	Xiao et al. (2021)		
		12 weeks				Egr-1,	liver in DN rats	
						TGF-β1		

TABLE 4 (Continued) Effects of drugs on SIRT1-interacting ncRNAs.

have shown that anthocyanins suppresses inflammatory responses in airways through decreasing activity of NF- κ B pathway via the miR-138-5p/SIRT1 axis (Liu Y. et al., 2022). Moreover, ginsenoside Rg3 can alleviate sepsis-related hepatic injury through modulation of TUG1/miR-200c-3p/SIRT1 axis (Wu P. et al., 2021). TUG1/miR-194/SIRT1 axis has been found to be targeted by dexmedetomidine hydrochloride to inhibit hepatocytes apoptosis and inflammatory responses (Gu et al., 2021). Additionally, the effects of berberine in amelioration of hepatic insulin resistance have been revealed to be mediated through regulation of miR-146b/SIRT1 axis (Sui et al., 2021).

Discussion

SIRT1 has a role as a deacetylase and is able to deacetylate a range of substrates. Thus, it participates in the regulation of a wide array of physiological processes such as gene expression, metabolic pathways and aging (Haigis and Guarente, 2006; Michan and Sinclair, 2007). This protein has functional interactions with lncRNAs, miRNAs and circRNAs. In fact, a complicated network exists between these noncoding RNAs and SIRT1. Hsa_circ_0115355/miR-326, hsa_circ_ 0115355/miR-487a-3p, HIPK3/miR-145, hsa_circ_0044235/miR-135b-5p, circ_0000296/miR-194-5p, circ_0001103/miR-375, CIDN/ miR-34a-5p, NOP10/miR-204, circ-0082374/miR-324 are examples of circRNA/miRNA pairs that interact with SIRT1. Similarly, GAS5/ miR-222-3p, GAS5/miR-579-3p, GAS5/miR-34a, MCM3AP-AS1/ miR-138-5p, TUG1/miR-9-5p, TUG1/miR-29c-3p, TUG1/miR-204, SNHG8/miR-425-5p, SNHG7/miR-9, SNHG7/miR-34a, SNHG15/ miR-141, SNHG10/miR-543, Oip5-as1/miR-29a, ILF3-AS1/miR-212-3p, ANRIL/miR-7-5p, UCA1/miR-204 and KCNQ1OT1/miR-124 are lncRNA/miRNA pairs that regulate expression of SIRT1 in different contexts. These interactions are possibly involved in the pathoetiology of a number of human disorders such as sepsis, cardiomyopathy, heart failure, non-alcoholic fatty liver disease, chronic hepatitis, cardiac fibrosis, myocardial ischemia/reperfusion injury, diabetes, ischemic stroke, immune-related disorders and cancers. In cancers, SIRT1-interacting non-coding RNAs not only affect cell proliferation but also regulate stemness and immunosuppressive responses in the tumor niche.

SIRT1 is a potential target for design of novel therapies. Most importantly, a number of drugs used for treatment of diverse asthma, sepsis, liver injury, insulin resistance, postmenopausal osteoporosis, Parkinson's disease, diabetic nephropathy and cancers exert their effects through modulation of non-coding RNAs/SIRT1 axis. Thus, identification of the interactions between non-coding RNAs and SIRT1 has practical significance in design of novel therapeutic strategies for diverse disorders. Remarkably, non-coding RNAs that modulate expression of SIRT1 are putative modulators of the response of patients to different drugs.

Author contributions

SG-F wrote the manuscript and revised it. MT and GS supervised and designed the study. HS, YP, and BH collected the data and designed the figures and tables. All authors read and approved the submitted version.

Acknowledgments

(The authors would like to thank the clinical Research Development Unit (CRDU) of Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran for their support, cooperation and assistance throughout the period of study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

References

Alshehri, A. S., El-Kott, A. F., El-Kenawy, A. E., Khalifa, H. S., and AlRamlawy, A. M. (2021). Cadmium chloride induces non-alcoholic fatty liver disease in rats by stimulating miR-34a/SIRT1/FXR/p53 axis. *Sci. Total Environ.* 784, 147182. doi:10. 1016/j.scitotenv.2021.147182

Asensio-Lopez, M. C., Sassi, Y., Soler, F., Fernandez del Palacio, M. J., Pascual-Figal, D., and Lax, A. (2021). The miRNA199a/SIRT1/P300/Yy1/sST2 signaling axis regulates adverse cardiac remodeling following MI. *Sci. Rep.* 11 (1), 3915–4014. doi:10.1038/ s41598-021-82745-9

Bai, Y., Chen, K., Zhan, J., and Wu, M. (2020). miR-122/SIRT1 axis regulates chondrocyte extracellular matrix degradation in osteoarthritis. *Biosci. Rep.* 40 (6), 20191908. doi:10.1042/BSR20191908

Bradbury, C., Khanim, F., Hayden, R., Bunce, C., White, D., Drayson, M., et al. (2005). Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. *Leukemia* 19 (10), 1751–1759. doi:10.1038/sj.leu.2403910

Chen, B., Wu, L., Cao, T., Zheng, H-M., and He, T. (2020b). MiR-221/SIRT1/ Nrf2 signal axis regulates high glucose induced apoptosis in human retinal microvascular endothelial cells. *BMC Ophthalmol.* 20 (1), 300–310. doi:10.1186/ s12886-020-01559-x

Chen, J., Li, Y., Li, Z., and Cao, L. (2020d). LncRNA MST1P2/miR-133b axis affects the chemoresistance of bladder cancer to cisplatin-based therapy via Sirt1/p53 signaling. *J. Biochem. Mol. Toxicol.* 34 (4), e22452. doi:10.1002/jbt.22452

Chen, L., Xie, W., Wang, L., Zhang, X., Liu, E., and Kou, Q. (2020a). MiRNA-133a aggravates inflammatory responses in sepsis by targeting SIRT1. *Int. Immunopharmacol.* 88, 106848. doi:10.1016/j.intimp.2020.106848

Chen, S., Luo, Z., and Chen, X. (2021). Hsa_circ_0044235 regulates the pyroptosis of rheumatoid arthritis via MiR-135b-5p-SIRT1 axis. *Cell Cycle* 20 (12), 1107–1121. doi:10.1080/15384101.2021.1916272

Chen, Z., He, M., Chen, J., Li, C., and Zhang, Q. (2020c). Long non-coding RNA SNHG7 inhibits NLRP3-dependent pyroptosis by targeting the miR-34a/SIRT1 axis in liver cancer. *Oncol. Lett.* 20 (1), 893–901. doi:10.3892/ol.2020.11635

Dai, Y., Ma, X., Zhang, J., Yu, S., Zhu, Y., and Wang, J. (2022). hsa_circ_ 0115355 promotes pancreatic β -cell function in patients with type 2 diabetes through the miR-145/SIRT1 axis. J. Clin. Laboratory Analysis 36, e24583. doi:10. 1002/jcla.24583

Ding, S., Liu, D., Wang, L., Wang, G., and Zhu, Y. (2020). Inhibiting microRNA-29a protects myocardial ischemia-reperfusion injury by targeting SIRT1 and suppressing oxidative stress and NLRP3-mediated pyroptosis pathway. *J. Pharmacol. Exp. Ther.* 372 (1), 128–135. doi:10.1124/jpet.119.256982

Dong, W., Zhang, H., Zhao, C., Luo, Y., and Chen, Y. (2021). Silencing of miR-150-5p ameliorates diabetic nephropathy by targeting SIRT1/p53/AMPK pathway. *Front. physiology* 12, 624989. doi:10.3389/fphys.2021.624989

Fu, Q., Pan, H., Tang, Y., Rong, J., and Zheng, Z. (2021). MiR-200a-3p aggravates DOX-induced cardiotoxicity by targeting PEG3 through SIRT1/NF- κ B signal pathway. *Cardiovasc. Toxicol.* 21 (4), 302–313. doi:10.1007/s12012-020-09620-3

Ghafouri-Fard, S., Hussen, B. M., Badrlou, E., Abak, A., and Taheri, M. (2021a). MicroRNAs as important contributors in the pathogenesis of colorectal cancer. *Biomed. Pharmacother.* 140, 111759. doi:10.1016/j.biopha.2021.111759

Ghafouri-Fard, S., Khoshbakht, T., Hussen, B. M., Sarfaraz, S., Taheri, M., and Ayatollahi, S. A. (2022). Circ_CDR1as: A circular RNA with roles in the carcinogenesis. *Pathology - Res. Pract.* 236, 153968. doi:10.1016/j.prp.2022.153968

Ghafouri-Fard, S., Taheri, M., Hussen, B. M., Vafaeimanesh, J., Abak, A., and Vafaee, R. (2021b). Function of circular RNAs in the pathogenesis of colorectal cancer. *Biomed. Pharmacother.* 140, 111721. doi:10.1016/j.biopha.2021.111721

Gu, X-X., Xu, X-X., Liao, H-H., Wu, R-N., Huang, W-M., Cheng, L-X., et al. (2021). Dexmedetomidine hydrochloride inhibits hepatocyte apoptosis and inflammation by activating the lncRNA TUG1/miR-194/SIRT1 signaling pathway. *J. Inflamm.* 18 (1), 20–12. doi:10.1186/s12950-021-00287-3

Haigis, M. C., and Guarente, L. P. (2006). Mammalian sirtuins—Emerging roles in physiology, aging, and calorie restriction. *Genes and Dev.* 20 (21), 2913–2921. doi:10. 1101/gad.1467506

Han, S., Lin, F., Ruan, Y., Zhao, S., Yuan, R., Ning, J., et al. (2021). miR-132-3p promotes the cisplatin-induced apoptosis and inflammatory response of renal tubular epithelial cells by targeting SIRT1 via the NF- κ B pathway. *Int. Immunopharmacol.* 99, 108022. doi:10.1016/j.intimp.2021.108022

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Hao, R., Song, X., Sun-Waterhouse, D., Tan, X., Li, F., and Li, D. (2021). Mir-34a/ sirt1/p53 signaling pathway contributes to cadmium-induced nephrotoxicity: A preclinical study in mice. *Environ. Pollut.* 282, 117029. doi:10.1016/j.envpol.2021. 117029

Huang, K., Yang, C., Zheng, J., Liu, X., Liu, J., Che, D., et al. (2021b). Effect of circular RNA, mmu_circ_0000296, on neuronal apoptosis in chronic cerebral ischaemia via the miR-194-5p/Runx3/Sirt1 axis. *Cell Death Discov.* 7 (1), 124–215. doi:10.1038/s41420-021-00507-y

Huang, L., Cai, H-A., Zhang, M-S., Liao, R-Y., Huang, X., and Hu, F-D. (2021a). Ginsenoside Rg1 promoted the wound healing in diabetic foot ulcers via miR-489–3p/ Sirt1 axis. J. Pharmacol. Sci. 147 (3), 271–283. doi:10.1016/j.jphs.2021.07.008

Huffman, D. M., Grizzle, W. E., Bamman, M. M., Kim, J-S., Eltoum, I. A., Elgavish, A., et al. (2007). SIRT1 is significantly elevated in mouse and human prostate cancer. *Cancer Res.* 67 (14), 6612–6618. doi:10.1158/0008-5472.CAN-07-0085

Hussen, B. M., Hidayat, H. J., and Ghafouri-Fard, S. (2022b). Identification of expression of CCND1-related lncRNAs in breast cancer. *Pathology - Res. Pract.* 236, 154009. doi:10.1016/j.prp.2022.154009

Hussen, B. M., Hidayat, H. J., Salihi, A., Sabir, D. K., Taheri, M., and Ghafouri-Fard, S. (2021). MicroRNA: A signature for cancer progression. *Biomed. Pharmacother.* 138, 111528. doi:10.1016/j.biopha.2021.111528

Hussen, B. M., Salihi, A., Abdullah, S. T., Rasul, M. F., Hidayat, H. J., Hajiesmaeili, M., et al. (2022a). Signaling pathways modulated by miRNAs in breast cancer angiogenesis and new therapeutics. *Pathology - Res. Pract.* 230, 153764. doi:10.1016/j.prp.2022. 153764

Kang, M., Ji, F., Sun, X., Liu, H., and Zhang, C. (2021). LncRNA SNHG15 promotes oxidative stress damage to regulate the occurrence and development of cerebral ischemia/reperfusion injury by targeting the miR-141/SIRT1 axis. *J. Healthc. Eng.* 2021, 6577799. doi:10.1155/2021/6577799

Li, C., Wang, F., Miao, P., Yan, L., Liu, S., Wang, X., et al. (2020b). miR-138 increases depressive-like behaviors by targeting SIRT1 in hippocampus. *Neuropsychiatric Dis. Treat.* 16, 949–957. doi:10.2147/NDT.S237558

Li, F., Zhang, L., Xue, H., Xuan, J., Rong, S., and Wang, K. (2021a). SIRT1 alleviates hepatic ischemia-reperfusion injury via the miR-182-mediated XBP1/NLRP3 pathway. *Mol. Therapy-Nucleic Acids.* 23, 1066–1077. doi:10.1016/j.omtn.2020.11.015

Li, H., Chou, P., Du, F., Sun, L., Liu, J., and Wang, W. (2021b). Depleting microRNA-183-3p improves renal tubulointerstitial fibrosis after acute kidney injury via SIRT1/PUMA/FOXO3a deacetylation. *Life Sci.* 269, 119017. doi:10. 1016/j.lfs.2021.119017

Li, T., Jiang, H., Li, Y., Zhao, X., and Ding, H. (2021c). Estrogen promotes lncRNA H19 expression to regulate osteogenic differentiation of BMSCs and reduce osteoporosis via miR-532-3p/SIRT1 axis. *Mol. Cell. Endocrinol.* 527, 111171. doi:10.1016/j.mce.2021. 111171

Li, T., Pang, Q., Liu, Y., Bai, M., Peng, Y., and Zhang, Z. (2021d). Sulforaphane protects human umbilical vein endothelial cells from oxidative stress via the miR-34a/ SIRT1 axis by upregulating nuclear factor erythroid-2-related factor 2. *Exp. Ther. Med.* 21 (3), 186. doi:10.3892/etm.2021.9617

Li, X., Zhang, W., Xu, K., and Lu, J. (2020a). miR-34a promotes liver fibrosis in patients with chronic hepatitis via mediating Sirt1/p53 signaling pathway. *Pathology-Research Pract.* 216 (5), 152876. doi:10.1016/j.prp.2020.152876

Liang, Y., Li, E., Zhang, H., Zhang, L., Tang, Y., and Wanyan, Y. (2020). Silencing of IncRNA UCA1 curbs proliferation and accelerates apoptosis by repressing SIRT1 signals by targeting miR-204 in pediatric AML. *J. Biochem. Mol. Toxicol.* 34 (3), e22435. doi:10.1002/jbt.22435

Liang, Y., Liu, H., Zhu, J., Song, N., Lu, Z., Fang, Y., et al. (2021). Inhibition of p53/ miR-34a/SIRT1 axis ameliorates podocyte injury in diabetic nephropathy. *Biochem. Biophysical Res. Commun.* 559, 48–55. doi:10.1016/j.bbrc.2021.04.025

Ling, H., Li, Q., Duan, Z-P., Wang, Y-J., Hu, B-Q., and Dai, X-G. (2021). LncRNA GAS5 inhibits miR-579-3p to activate SIRT1/PGC-1a/Nrf2 signaling pathway to reduce cell pyroptosis in sepsis-associated renal injury. *Am. J. Physiology-Cell Physiology* 321 (7), C117–C133. doi:10.1152/ajpcell.00394.2020

Liu, M., Zhang, Y., Cao, X., Shi, T., and Yan, Y. (2022a). miR-197 participates in lipopolysaccharide-induced cardiomyocyte injury by modulating SIRT1. *Cardiol. Res. Pract.* 2022, 7687154. doi:10.1155/2022/7687154

Liu, Y., Zhang, M., Zhang, H., Qian, X., Luo, L., and He, Z. (2022b). Cancer metastases from lung adenocarcinoma disappeared after molecular targeted therapy: A successfully

clinical treatment experience. Int. Archives Allergy Immunol. 183 (5), 539–546. doi:10. 2147/PGPM.S367978

Lu, R-H., Xiao, Z-Q., Zhou, J-D., Yin, C-Q., Chen, Z-Z., Tang, F-J., et al. (2020). MiR-199a-5p represses the stemness of cutaneous squamous cell carcinoma stem cells by targeting Sirt1 and CD44ICD cleavage signaling. *Cell Cycle* 19 (1), 1–14. doi:10.1080/15384101.2019.1689482

Ma, W., Zhang, W., Cui, B., Gao, J., Liu, Q., Yao, M., et al. (2021). Functional delivery of lncRNA TUG1 by endothelial progenitor cells derived extracellular vesicles confers anti-inflammatory macrophage polarization in sepsis via impairing miR-9-5p-targeted SIRT1 inhibition. *Cell death Dis.* 12 (11), 1056–1110. doi:10.1038/s41419-021-04117-5

Meng, F., Yang, M., Chen, Y., Chen, W., and Wang, W. (2021). miR-34a induces immunosuppression in colorectal carcinoma through modulating a SIRT1/NF- κ B/B7-H3/TNF- α axis. *Immunotherapy* 70 (8), 2247–2259. doi:10.1007/s00262-021-02862-2

Michan, S., and Sinclair, D. (2007). Sirtuins in mammals: Insights into their biological function. *Biochem. J.* 404 (1), 1–13. doi:10.1042/BJ20070140

Mo, Y., Liu, B., Qiu, S., Wang, X., Zhong, L., Han, X., et al. (2020). Down-regulation of microRNA-34c-5p alleviates neuropathic pain via the SIRT1/STAT3 signaling pathway in rat models of chronic constriction injury of sciatic nerve. *J. Neurochem.* 154 (3), 301–315. doi:10.1111/jnc.14998

Niu, X., Pu, S., Ling, C., Xu, J., Wang, J., Sun, S., et al. (2020). lncRNA Oip5-as1 attenuates myocardial ischaemia/reperfusion injury by sponging miR-29a to activate the SIRT1/AMPK/PGC1 α pathway. *Cell Prolif.* 53 (6), e12818. doi:10. 1111/cpr.12818

Pillarisetti, S. (2008). A review of Sirt1 and Sirt1 modulators in cardiovascular and metabolic diseases. *Recent Pat. Cardiovasc. Drug Discov. Discontin.* 3 (3), 156–164. doi:10.2174/157489008786263989

Purushotham, A., Schug, T. T., Xu, Q., Surapureddi, S., Guo, X., and Li, X. (2009). Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. *Cell metab.* 9 (4), 327–338. doi:10.1016/j.cmet.2009.02.006

Qazi, T. J., Lu, J., Duru, L., Zhao, J., and Qing, H. (2021). Upregulation of mir-132 induces dopaminergic neuronal death via activating SIRT1/P53 pathway. *Neurosci. Lett.* 740, 135465. doi:10.1016/j.neulet.2020.135465

Qi, M., He, L., Ma, X., and Li, Z. (2020). MiR-181a-5p is involved in the cardiomyocytes apoptosis induced by hypoxia-reoxygenation through regulating SIRT1. *Biosci. Biotechnol. Biochem.* 84 (7), 1353–1361. doi:10.1080/09168451.2020. 1750943

Qu, L. H., Hong, X., Zhang, Y., Cong, X., Xiang, R. L., Mei, M., et al. (2021). C1q/ tumor necrosis factor-related protein-6 attenuates TNF- α -induced apoptosis in salivary acinar cells via AMPK/SIRT1-modulated miR-34a-5p expression. *J. Cell. Physiology* 236 (8), 5785–5800. doi:10.1002/jcp.30262

Rahman, S., and Islam, R. (2011). Mammalian Sirt1: Insights on its biological functions. Cell Commun. Signal. 9 (1), 11-18. doi:10.1186/1478-811X-9-11

Sabaie, H., Salkhordeh, Z., Asadi, M. R., Ghafouri-Fard, S., Amirinejad, N., Askarinejad Behzadi, M., et al. (2021). Long non-coding RNA- associated competing endogenous RNA axes in T-cells in multiple sclerosis. *Front. Immunol.* 12, 770679. doi:10.3389/fimmu.2021.770679

Sayad, A., Najafi, S., Hussen, B. M., Jamali, E., Taheri, M., and Ghafouri-Fard, S. (2022). The role of circular RNAs in pancreatic cancer: New players in tumorigenesis and potential biomarkers. *Pathology - Res. Pract.* 232, 153833. doi:10.1016/j.prp.2022. 153833

Shi, J., Cao, F., Chang, Y., Xin, C., Jiang, X., Xu, J., et al. (2021). Long non-coding RNA MCM3AP-AS1 protects chondrocytes ATDC5 and CHON-001 from IL-1 β -induced inflammation via regulating miR-138-5p/SIRT1. *Bioengineered* 12 (1), 1445–1456. doi:10.1080/21655979.2021.1905247

Shu, L., Zhang, W., Huang, C., Huang, G., Su, G., and Xu, J. (2020). lncRNA ANRIL protects H9c2 cells against hypoxia-induced injury through targeting the miR-7-5p/ SIRT1 axis. *J. Cell. physiology* 235 (2), 1175–1183. doi:10.1002/jcp.29031

Stünkel, W., Peh, B. K., Tan, Y. C., Nayagam, V. M., Wang, X., Salto-Tellez, M., et al. (2007). Function of the SIRT1 protein deacetylase in cancer. *Biotechnol. J. Healthc. Nutr. Technol.* 2 (11), 1360–1368. doi:10.1002/biot.200700087

Sui, M., Jiang, X., Sun, H., Liu, C., and Fan, Y. (2021). Berberine ameliorates hepatic insulin resistance by regulating microRNA-146b/SIRT1 pathway. *Diabetes, metabolic syndrome Obes. targets Ther.* 14, 2525–2537. doi:10.2147/DMSO.S313068

Sun, G., Yang, L., Wei, S., Jin, H., Li, B., and Li, H. (2021). miR-425 regulates lipophagy via SIRT1 to promote sorafenib resistance in liver cancer. *Oncol. Lett.* 22 (4), 695–710. doi:10.3892/ol.2021.12956

Tian, J., Liu, Y., Wang, Z., Zhang, S., Yang, Y., Zhu, Y., et al. (2021). LncRNA Snhg8 attenuates microglial inflammation response and blood–brain barrier damage in ischemic stroke through regulating miR-425-5p mediated SIRT1/NF- κ B signaling. J. Biochem. Mol. Toxicol. 35 (5), e22724. doi:10.1002/jbt.22724

Tufekci, K. U., Eltutan, B. I., Isci, K. B., and Genc, S. (2021). Resveratrol inhibits NLRP3 inflammasome-induced pyroptosis and miR-155 expression in microglia through Sirt1/AMPK pathway. *Neurotox. Res.* 39 (6), 1812–1829. doi:10.1007/s12640-021-00435-w

Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S-I., Frye, R. A., Pandita, T. K., et al. (2001). hSIR2SIRT1 functions as an NAD-dependent p53 deacetylase. *Cell* 107 (2), 149–159. doi:10.1016/s0092-8674(01)00527-x

Wang, B., Li, B., and Si, T. (2020). Knockdown of circ0082374 inhibits cell viability, migration, invasion and glycolysis in glioma cells by miR-326/SIRT1. *Brain Res.* 1748, 147108. doi:10.1016/j.brainres.2020.147108

Wang, C., Guo, X., Wang, Y., and Wang, H. (2021c). Silencing of miR-324-5p alleviates rat spinal cord injury by Sirt1. *Neurosci. Res.* 173, 34–43. doi:10.1016/j.neures. 2021.05.010

Wang, H., He, F., Liang, B., Jing, Y., Zhang, P., Liu, W., et al. (2021g). LincRNA-p21 alleviates atherosclerosis progression through regulating the miR-221/SIRT1/ Pcsk9 axis. J. Cell. Mol. Med. 25 (19), 9141–9153. doi:10.1111/jcmm.16771

Wang, R., Xu, Y., Niu, X., Fang, Y., Guo, D., Chen, J., et al. (2021b). miR-22 inhibition alleviates cardiac dysfunction in doxorubicin-induced cardiomyopathy by targeting the sirt1/PGC-1a pathway. *Front. Physiology* 12, 646903. doi:10.3389/fphys. 2021.646903

Wang, R., Xu, Y., Zhang, W., Fang, Y., Yang, T., Zeng, D., et al. (2021a). Inhibiting miR-22 alleviates cardiac dysfunction by regulating Sirt1 in septic cardiomyopathy. *Front. Cell Dev. Biol.* 9, 650666. doi:10.3389/fcell.2021.650666

Wang, S., Yi, P., Wang, N., Song, M., Li, W., and Zheng, Y. (2021h). LncRNA TUG1/ miR-29c-3p/SIRT1 axis regulates endoplasmic reticulum stress-mediated renal epithelial cells injury in diabetic nephropathy model in vitro. PloS one 16 (6), e0252761. doi:10.1371/journal.pone.0252761

Wang, Y., Yang, Z., Zhang, K., Wan, Y., Zhou, Y., and Yang, Z. (2021d). miR-135a-5p inhibitor protects glial cells against apoptosis via targeting SIRT1 in epilepsy. *Exp. Ther. Med.* 21 (5), 431–438. doi:10.3892/etm.2021.9848

Wang, Z., Chen, R., Xu, Z., Ru, W., Tian, H., Yang, F., et al. (2021e). MiR-155-5p promotes renal interstitial fibrosis in obstructive nephropathy via inhibiting SIRT1 signaling pathway. *J. Recept. Signal Transduct.* 41 (5), 466–475. doi:10.1080/10799893.2020.1825491

Wang, Z., Shi, D., Zhang, N., Yuan, T., and Tao, H. (2021f). MiR-217 promotes endothelial cell senescence through the SIRT1/p53 signaling pathway. *J. Mol. Histology* 52 (2), 257–267. doi:10.1007/s10735-020-09945-x

Wei, Y-J., Wang, J-F., Cheng, F., Xu, H-J., Chen, J-J., Xiong, J., et al. (2021). miR-124-3p targeted SIRT1 to regulate cell apoptosis, inflammatory response, and oxidative stress in acute myocardial infarction in rats via modulation of the FGF21/ CREB/PGC1a pathway. *J. physiology Biochem.* 77 (4), 577–587. doi:10.1007/ s13105-021-00822-z

Wu, L., Zhang, G., Guo, C., Zhao, X., Shen, D., and Yang, N. (2020). MiR-128-3p mediates TNF- α -induced inflammatory responses by regulating Sirt1 expression in bone marrow mesenchymal stem cells. *Biochem. biophysical Res. Commun.* 521 (1), 98–105. doi:10.1016/j.bbrc.2019.10.083

Wu, P., Yu, X., Peng, Y., Wang, Q-L., Deng, L-T., and Xing, W. (2021b). Ginsenoside Rg3 alleviates septic liver injury by regulating the lncRNA TUG1/miR-200c-3p/SIRT1 axis. *J. Inflamm.* 18 (1), 31–13. doi:10.1186/s12950-021-00296-2

Wu, Z., Chen, J., Zhao, W., Zhuo, C. H., and Chen, Q. (2021a). Inhibition of miR-181a attenuates sepsis-induced inflammation and apoptosis by activating Nrf2 and inhibiting NF-κB pathways via targeting SIRT1. *Kaohsiung J. Med. Sci.* 37 (3), 200–207. doi:10. 1002/kjm2.12310

Xiang, Q., Kang, L., Wang, J., Liao, Z., Song, Y., Zhao, K., et al. (2020). CircRNA-CIDN mitigated compression loading-induced damage in human nucleus pulposus cells via miR-34a-5p/SIRT1 axis. *EBioMedicine* 53, 102679. doi:10.1016/j.ebiom. 2020.102679

Xiao, S., Yang, Y., Liu, Y-T., and Zhu, J. (2021). Liraglutide regulates the kidney and liver in diabetic nephropathy rats through the miR-34a/SIRT1 pathway. *J. Diabetes Res.* 2021, 8873956. doi:10.1155/2021/8873956

Xu, H., Zhang, J., Shi, X., Li, X., and Zheng, C. (2021a). NF-κB inducible miR-30b-5p aggravates joint pain and loss of articular cartilage via targeting SIRT1-FoxO3amediated NLRP3 inflammasome. *Aging (Albany NY)* 13 (16), 20774–20792. doi:10. 18632/aging.203466

Xu, J., Wang, X., Wang, W., Zhang, L., and Huang, P. (2021b). Candidate oncogene circularNOP10 mediates gastric cancer progression by regulating miR-204/ SIRT1 pathway. J. Gastrointest. Oncol. 12 (4), 1428–1443. doi:10.21037/jgo-21-422

Yamamoto, H., Schoonjans, K., and Auwerx, J. (2007). Sirtuin functions in health and disease. *Mol. Endocrinol.* 21 (8), 1745–1755. doi:10.1210/me.2007-0079

Yang, Y., and Li, L. (2021). Depleting microRNA-146a-3p attenuates lipopolysaccharide-induced acute lung injury via up-regulating SIRT1 and mediating NF- κ B pathway. *J. Drug Target.* 29 (4), 420–429. doi:10.1080/1061186X.2020.1850738

Yang, Y-L., Wang, P-W., Wang, F-S., Lin, H-Y., and Huang, Y-H. (2020). miR-29a modulates GSK3 β /SIRT1-linked mitochondrial proteostatic stress to ameliorate mouse non-alcoholic steatohepatitis. *Int. J. Mol. Sci.* 21 (18), 6884. doi:10.3390/ ijms21186884

Yang, Z., Lin, S-D., Zhan, F., Liu, Y., and Zhan, Y-W. (2021). LncRNA GAS5 alleviates rheumatoid arthritis through regulating miR-222-3p/Sirt1 signalling axis. *Autoimmunity* 54 (1), 13–22. doi:10.1080/08916934.2020.1846183

Yin, Q-H., Zhou, Y., and Li, Z-Y. (2021). miR-373 suppresses cell proliferation and apoptosis via regulation of SIRT1/PGC-1α/NRF2 axis in pancreatic cancer. *Cell J.* (*Yakhteh*) 23 (2), 199–210. doi:10.22074/cellj.2021.7038

Yuan, T., Zhang, L., Yao, S., Deng, S. Y., and Liu, J. Q. (2020). miR-195 promotes LPSmediated intestinal epithelial cell apoptosis via targeting SIRT1/eIF2a. *Int. J. Mol. Med.* 45 (2), 510–518. doi:10.3892/ijmm.2019.4431

Zhan, H., Huang, F., Niu, Q., Jiao, M., Han, X., Zhang, K., et al. (2021). Downregulation of miR-128 ameliorates Ang II-induced cardiac remodeling via SIRT1/PIK3R1 multiple targets. *Oxidative Med. Cell. Longev.* 2021, 8889195. doi:10. 1155/2021/8889195

Zhang, H., Yang, X., Xu, Y., and Li, H. (2021d). KCNQ10T1 regulates the retinoblastoma cell proliferation, migration and SIRT1/JNK signaling pathway by targeting miR-124/SP1 axis. *Biosci. Rep.* 41 (1), 20201626. doi:10.1042/BSR20201626

Zhang, H., Zhang, X. M., Zong, Dd, Xy, Ji, Jiang, H., Zhang, F. Z., et al. (2021a). miR-34a-5p up-regulates the IL-1 β /COX2/PGE2 inflammation pathway and induces the release of CGRP via inhibition of SIRT1 in rat trigeminal ganglion neurons. *FEBS Open bio* 11 (1), 300–311. doi:10.1002/2211-5463.13027

Zhang, H. G., Wang, F. J., Wang, Y., Zhao, Z. X., and Qiao, P. F. (2021c). lncRNA GAS5 inhibits malignant progression by regulating macroautophagy and forms a negative feedback regulatory loop with the miR-34a/mTOR/SIRT1 pathway in colorectal cancer. *Oncol. Rep.* 45 (1), 202–216. doi:10.3892/or.2020.7825

Zhang, J., Yang, Z., Fang, K., Shi, Z., Ren, D., and Sun, J. (2020c). Long noncoding RNA ILF3-AS1 regulates myocardial infarction via the miR-212-3p/SIRT1 axis and PI3K/Akt signaling pathway. *Eur. Rev. Med. Pharmacol. Sci.* 24 (5), 2647–2658. doi:10. 26355/eurrev_202003_20534

Zhang, L., Guo, Y., Shi, S., Zhuge, Y., Chen, N., Ding, Z., et al. (2022). Tetrahydroxy stilbene glycoside attenuates endothelial cell premature senescence induced by H2O2 through the microRNA-34a/SIRT1 pathway. *Sci. Rep.* 12 (1), 1708–8. doi:10. 1038/s41598-022-05804-9

Zhang, M., Cao, M., Kong, L., Liu, J., Wang, Y., Song, C., et al. (2020a). MiR-204-5p promotes lipid synthesis in mammary epithelial cells by targeting SIRT1. *Biochem. Biophysical Res. Commun.* 533 (4), 1490–1496. doi:10.1016/j.bbrc.2020. 10.056

Zhang, M., Mou, L., Liu, S., Sun, F., and Gong, M. (2021b). Circ_0001103 alleviates IL-1 β -induced chondrocyte cell injuries by upregulating SIRT1 via targeting miR-375. *Clin. Immunol.* 227, 108718. doi:10.1016/j.clim.2021.108718

Zhang, Y., Ma, Y., Gu, M., and Peng, Y. (2020d). lncRNA TUG1 promotes the Brown remodeling of white adipose tissue by regulating miR-204-targeted SIRT1 in diabetic mice. *Int. J. Mol. Med.* 46 (6), 2225–2234. doi:10.3892/ijmm.2020.4741

Zhang, Z., Nong, L., Chen, M-L., Gu, X-L., Zhao, W-W., Liu, M-H., et al. (2020b). Long noncoding RNA SNHG10 sponges miR-543 to upregulate tumor suppressive SIRT1 in nonsmall cell lung cancer. *Cancer Biotherapy Radiopharm.* 35 (10), 771–775. doi:10.1089/cbr.2019.3334

Zheng, M., Tan, J., Liu, X., Jin, F., Lai, R., and Wang, X. (2021). miR-146a-5p targets Sirt1 to regulate bone mass. *Bone Rep.* 14, 101013. doi:10.1016/j.bonr.2021. 101013

Zhou, F., Wang, Y-K., Zhang, C-G., and Wu, B-Y. (2021). miR-19a/b-3p promotes inflammation during cerebral ischemia/reperfusion injury via SIRT1/FoxO3/ SPHK1 pathway. *J. neuroinflammation* 18 (1), 122–213. doi:10.1186/s12974-021-02172-5

Zhou, T., Wang, S., Lu, K., and Yin, C. (2020). Long non-coding RNA SNHG7 alleviates oxygen and glucose deprivation/reoxygenation-induced neuronal injury by modulating miR-9/SIRT1 Axis in PC12 cells: Potential role in ischemic stroke. *Neuropsychiatric Dis. Treat.* 16, 2837–2848. doi:10.2147/NDT. S273421

Zhuang, L., Wang, Z., Hu, X., Yang, Q., Pei, X., and Jin, G. (2021). CircHIPK3 alleviates high glucose toxicity to human renal tubular epithelial HK-2 cells through regulation of miR-326/miR-487a-3p/SIRT1. *Targets Ther.* 14, 729–740. doi:10.2147/DMSO.S289624

Glossary

Glossary		NAFLD	Non-Alcoholic Fatty Liver Disease
ANT	Adjacent normal tissue	CHC	Chronic Hepatitis C
PPARa	peroxisome proliferators-activated receptor <i>a</i>	SCMP	Septic Cardiomyopathy
CTRP6	C1q/Tumor Necrosis Factor-Related Protein-6	CHF	Congestive Heart Failure
HMGCoAR	β -Hydroxy β -Methylglutaryl-CoA Reductase	HF	Heart Failure
hUC-MSCs	Human Umbilical Cord-Derived Mesenchymal Stem Cell	MI	Myocardial Injury
HBE	Human Bronchial Epithelial	AMI	Acute Myocardial Infarction
hTERT RPE-1	Human Retinal Pigment Epithelial Cell Line	AKI	Osteoarthritis (OA), Acute Kidney Injury
FLSs	Fibroblast-Like Synoviocytes	DN	Diabetic Nephropathy
PBMCs	Human Peripheral Blood Mononuclear Cells	DR	Diabetic Retinopathy
BMSCs	Human Bone Marrow Mesenchymal Stem Cells	SCI	Spinal Cord Injury
ALP	Alkaline Phosphatase	CCIS	Chronic Constriction Injury of Sciatic Nerve
МРО	Myeloperoxidase	MDD	Major Depressive Disorder
CECs	Cardiac Endothelial Cells	DFUs	Diabetic Foot Ulcers
CFs	Cardiac Fibroblasts	ALI	Acute Lung Injury
CMs	Cardiomyocytes	UUO	Unilateral Ureteral Obstruction
CGRP	Calcitonin Generated Peptide	РСа	Pancreatic Cancer
PGE2	Prostaglandin E2	CRC	Colorectal Cancer
BMEC	Microvascular Endothelial Cell	cSCC	Cutaneous Squamous Cell Carcinoma
HASMCs	Human Aortic Smooth Muscle Cells	RB	retinoblastoma
HIF-1a	Hypoxia-Inducible Factor-1 a	T2DM	Type 2 Diabetes Mellitus
Egr-1	Early Growth Response-1	CCI	Chronic Cerebral Ischemia
UA	Uric Acid	IDD	Intervertebral Disc Degeneration
UREA	Urea	GC	Gastric Cancer
Nrf2	Nuclear Factor Erythroid-2-Related Factor 2	Ш	Liver Injury
ARE	Antioxidant Response Element	HIR	Hepatic Insulin Resistance
NRVMs	Neonatal Rats Ventricular Myocytes	РМОР	Postmenopausal osteoporosis
BMSCs	Bone Marrow Mesenchymal Stem Cells	PD	Parkinson's Disease
hRMEC	Human Retinal Microvascular Endothelial Cells	BLC	Bladder Cancer
CUMS	Chronic Unpredictable Mild Stress		
HBDH	Hydroxybutyratse Dehydrogenase		
CK-MB	Creatine Kinase MB Activity		
NHSF	Normal Human Skin Fibroblast		
RA	Rheumatoid Arthritis		
AS	Atherosclerosis		
SARI	Sepsis-associated renal injury		

Frontiers in Genetics

Pediatric acute myeloid leukemia

Hepatocellular carcinoma

Non-small cell lung cancer

Ischemia-reperfusion

AML

нсс

I/R

NSCLC